Tofogliflozin Modulates Gut Microbial Amino Acid Metabolism in MASLD: JOG | August 2026

Introduction:

The gut–liver axis plays a central role in the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). While previous studies have focused on changes in gut bacterial composition, emerging evidence suggests that microbial metabolic function may be a more important determinant of liver injury. This study explored how the SGLT2 inhibitor tofogliflozin influences gut microbial metabolism and its relationship with liver molecular pathways and fibrosis in patients with MASLD and type 2 diabetes.

Why was this study needed?

The mechanisms linking gut dysbiosis and liver fibrosis in MASLD remain incompletely understood.

Most microbiome studies focus on bacterial species rather than their metabolic functions.

Functional microbial pathways may better explain disease progression and treatment response.

SGLT2 inhibitors improve MASLD, but their effects on the gut microbiome are not fully defined.

Identifying microbiome-derived therapeutic targets could lead to novel treatment strategies.

Results:

Microbial metabolic pathways, rather than bacterial composition, showed the strongest differences between patients with MASLD and healthy individuals.

Amino acid metabolism, particularly phenylalanine metabolism, emerged as the key microbial pathway associated with liver disease severity.

Increased microbial phenylalanine degradation was associated with more advanced liver fibrosis and correlated with multiple hepatic molecular pathways involved in MASLD, including mitochondrial dysfunction.

In contrast, phenylalanine biosynthesis was associated with less severe liver fibrosis, suggesting a potentially protective microbial metabolic signature.

Both tofogliflozin and glimepiride improved liver histology, but tofogliflozin uniquely shifted microbial metabolism toward increased phenylalanine biosynthesis, a pattern linked to lower fibrosis.

Importantly, these metabolic improvements occurred without major changes in gut bacterial species, indicating that microbial function may be more relevant than microbiome composition.

Clinical Impact:

This study shifts the focus of MASLD research from "which bacteria are present" to "what the microbiome is doing." The findings suggest that microbial amino acid metabolism, particularly phenylalanine metabolism, may serve as both a biomarker and therapeutic target for liver fibrosis. The ability of tofogliflozin to favorably modify microbial metabolic function provides a novel mechanism that may contribute to its hepatic benefits beyond glucose lowering. Future therapies may increasingly target microbial metabolic pathways rather than attempting to alter bacterial composition alone.

Bottom Line:

In MASLD, gut microbial metabolic function is more closely linked to liver fibrosis than microbial composition. Tofogliflozin favorably alters microbial phenylalanine metabolism toward a profile associated with reduced fibrosis, highlighting microbial metabolism as a promising new therapeutic target in the gut–liver axis.